Louis-Philippe Boulet, Carl Abbott, Guy Brusselle, Dawn Edwards, John Oppenheimer, Ian D Pavord, Emilio Pizzichini, Hironori Sagara, David Slade, Michael E Wechsler, Peter G Gibson
BACKGROUND: Findings from CAPTAIN (NCT02924688) suggest treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) differs according to baseline type 2 (T2) inflammation markers in patients with moderate-to-severe asthma. Understanding how other patient physiologic and clinical characteristics affect response to inhaled therapies may guide physicians toward a personalized approach for asthma management. OBJECTIVE: To investigate, using CAPTAIN data, the predictive value of key demographic and baseline physiologic variables in patients with asthma (lung function, bronchodilator reversibility, age, age at asthma onset) on response to addition of the long-acting muscarinic antagonist UMEC to inhaled corticosteroid/long-acting β2 -agonist combination FF/VI, or doubling FF dose...
February 1, 2024: Journal of Allergy and Clinical Immunology in Practice